Viridian Therapeutics 3Q 2026: Revenue $25.8M, Net loss $101.2M, EPS $(0.81) — 10-Q Summary

Viridian Therapeutics reported 3Q 2026 revenue of $25.8M, a net loss of $101.2M, and EPS of $(0.81). This compares to $70.6M revenue and a $34.6M net loss in the prior-year quarter. The company's newly launched drug, veligrotug, generated $24.7M in U.S. sales. Viridian also announced positive Phase 3 trial results for elegrobart and plans for upcoming trials.

Original reporting
Published Nov 4, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Viridian Therapeutics 3Q 2026: Revenue $25.8M, Net loss $101.2M, EPS $(0.81) — 10-Q Summary — source image
Decision brief

The 30-second read

$VRDNNeutralMed
01

Why it matters

The Q3 2026 earnings release provides the first public numbers for the post‑approval quarter, setting a baseline for future performance.

02

Market read

The report offers fresh data on a micro‑cap biotech, combining a loss with a regulatory win, which may affect short‑term trading and longer‑term valuation.

03

What to watch

Potential future revenue from upcoming trial readouts and the upcoming BLA filing in Q1 2027.

Relevance 7/10Novelty 8/10Timing: after‑hours release

Background

Viridian Therapeutics (VRDN) is a clinical‑stage biotech focused on rare endocrine disorders. The company recently received FDA approval for its veligrotug product, Lumvoa.

Company-level read

Ticker impact

$VRDNNeutralHigh confidence
Context

Viridian Therapeutics filed its 10‑Q reporting Q3 2026 results, including $25.8M revenue, $101.2M net loss and FDA approval of Lumvoa.

Expected impact

likely pressure as the market prices in the larger-than-expected loss, offset partially by the FDA approval and new product revenue.

Evidence & confidence

Quarterly results are the first public disclosure of these numbers; the loss magnitude is material for a micro‑cap, and FDA approval is a significant catalyst.

Market effects

Highlights progress in the biotech/rare‑disease space and may influence peer valuations.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

Despite the loss, the FDA approval and early sales could drive a short‑term rally if investors focus on the upside.

Key entities

  • Viridian Therapeutics

    Biotech firm reporting Q3 2026 results and FDA approval.

  • FDA

    Approved Lumvoa for commercial use.

Related articles

$VRDNMedAI 8/10

Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says

Jefferies highlights Viridian Therapeutics' (VRDN) VRDN-008 as a potential best-in-class FcRn inhibitor, with an extended half-life supporting eight-week dosing. Phase I results showed a 74% peak IgG reduction sustained for eight weeks. The company plans to start a registrational study in gMG in mid-2027, with potential approval by 2031. Jefferies maintains a $35 price target, excluding contributions from VRDN's broader pipeline.

$VRDNMedAI 8/10

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing - VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after sub

$VRDNHighAI 8/10

Viridian reports phase 1 results for VRDN-008 autoimmune drug

Viridian Therapeutics (VRDN) reported phase 1 trial results for VRDN-008, showing a 74% reduction in IgG and a half-life of 15-18 days. No serious adverse events were observed. The company plans to start pivotal trials in 2027, targeting myasthenia gravis first. VRDN-008 will be administered using Enable Injections’ enFuse device, licensed exclusively by Viridian.